Pharmacodynamic Activity of [ <sup>18</sup> F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With <i>BRCA1/2</i> -Mutated Breast Cancer Receiving Talazoparib
We conclude that [<sup>18</sup>F]FTT can image target engagement by PARPi, but larger studies are needed to determine whether [<sup>18</sup>F]FTT uptake can predict response to PARPi and whether uptake of [<sup>18</sup>F]FTT in bone marrow may be an early predictor of hematologic toxicity.
Authors
- Franklin C. Wong (ORCID: https://orcid.org/0000-0002-3449-5836)
- Jennifer K. Litton (ORCID: https://orcid.org/0000-0001-8390-4985)
- Lilie L. Lin (ORCID: https://orcid.org/0000-0001-7681-8966)
- Ruitao Lin (ORCID: https://orcid.org/0000-0003-2244-131X)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1200/po.24.00303
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Pfizer
- AstraZeneca
- University of Pennsylvania
- Varian Medical Systems
- University of Texas MD Anderson Cancer Center